New analysis from landmark MA-17 trial shows significant improvements in overall survival, disease-free survival and distant metastases.

Novartis to show strong support and participation in the Run for the Cure through fundraising and employee participation in support of Canadian Breast Cancer Foundation.

Diovan now approved to reduce cardiovascular death in patients at high risk (with heart failure or left ventricular dysfunction) following a heart attack. Diovan* is the world’s most prescribed angiotensin-receptor blocker (ARB) for mild-to-moderate hypertension.

Employees will cycle 600-km from Toronto to Montreal to raise funds for the Canadian Breast Cancer Foundation

Aclasta superiority in Paget's disease of the bone proven in head-to-head study published in The New England Journal of Medicine